Pumitamig vs. Durvalumab w/unresectable Stage II NSCLC w/o progression after platinum based concurrent chemoradiation

A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.inum-based, concurrent chemoradiation therapy

Disease Types: Lung

Available at: Blacksburg, Roanoke, Salem, Wytheville, Alleghany

A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

For More Information:

https://clinicaltrials.gov/study/NCT07361497?cond=Lung%20Cancer&term=Pumitamig%20&viewType=Card&rank=3